

Membrane phospholipid composition of Pseudomonas aeruginosa grown in a cystic fibrosis mucus-mimicking medium

Estelle Deschamps, Annick Schaumann, Isabelle Schmitz-Afonso, Carlos Afonso, Emmanuelle Dé, Corinne Loutelier-Bourhis, Stephane Alexandre

▶ To cite this version:

Estelle Deschamps, Annick Schaumann, Isabelle Schmitz-Afonso, Carlos Afonso, Emmanuelle Dé, et al.. Membrane phospholipid composition of Pseudomonas aeruginosa grown in a cystic fibrosis mucus-mimicking medium. Biochimica et Biophysica Acta:Biomembranes, 2021, 1863 (1), pp.183482. 10.1016/j.bbamem.2020.183482 . hal-03024926

HAL Id: hal-03024926 https://hal.science/hal-03024926v1

Submitted on 9 Dec 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Membrane phospholipid composition of *Pseudomonas aeruginosa* grown in a cystic fibrosis
 mucus-mimicking medium

3

4 Estelle Deschamps^{a,b}, Annick Schaumann^a, Isabelle Schmitz-Afonso^b, Carlos Afonso^b,
5 Emmanuelle Dé^a, Corinne Loutelier-Bourhis^b, Stéphane Alexandre^{a,*}

6

7 a Normandie Univ, PBS, UMR 6270 and FR 3038, Université de Rouen, INSA de Rouen,

8 CNRS, CURIB, Bvd De Broglie, 76821 Mont-Saint-Aignan, Cedex, France

9 b Normandie Univ, COBRA, UMR 6014 and FR 3038, Université de Rouen, INSA de

10 Rouen, CNRS, IRCOF, 1 rue Tesnière, 76821 Mont-Saint-Aignan, Cedex, France

11

12 <u>Corresponding author</u>: Stéphane Alexandre, <u>stephane.alexandre@univ-rouen.fr</u>

13

14 Keywords: Pseudomonas aeruginosa, CF sputum, membrane lipids, antibiotic resistance,

15 culture medium, mass spectrometry

16

Abbreviations: CF, cystic fibrosis; MHB, Mueller Hilton broth; SCFM, synthetic cystic fibrosis 17 medium; DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; SCFM-PC, DOPC complemented 18 SCFM; LB, lysogeny broth; ASM, artificial sputum medium; PE, phosphatidylethanolamines; 19 PC, phosphatidylcholines; PG, phosphatidylglycerols; CL, cardiolipins; LC-MS, liquid 20 21 chromatography - mass spectrometry; MS/MS, tandem mass spectrometry; MIC, minimal inhibitory concentration; ESI-MS, electrospray ionisation-mass spectrometry; PAK, P. 22 aeruginosa strain PAK; CFU, colony forming units; OD600, optical density at 600 nm; AFM, 23 24 atomic force microscopy; (n), number of replicates.

25

Received 3 June 2020; Received in revised form 18 September 2020; Accepted 21 September
2020 Available online 28 September 2020

28 ABSTRACT

2 Page 1 | 42 3 4 *Background: Pseudomonas aeruginosa* is a bacterium able to induce serious pulmonary infections in cystic fibrosis (*CF*) patients. This bacterium is very often antibiotic resistant, partly because of its membrane impermeability, which is linked to the membrane lipid composition. This work aims to study the membrane phospholipids of *P. aeruginosa* grown in *CF* sputum-like media.


Methods: Three media were used: Mueller Hilton broth (MHB), synthetic cystic fibrosis medium (SCFM) and 1,2- dioleoyl-*sn*-glycero-3-phosphocholine (DOPC) complemented SCFM (SCFM-PC). Lipids were extracted and LC-MS/MS analyses were performed. Growth curves, atomic force microscopy images and minimal inhibitory concentration determination were performed in order to compare the growth and potentially link lipid modifications to antibiotic resistance.

40 *Results:* Semi-quantification showed phospholipid quantity variation depending on the 41 growth medium. Phosphatidylcholines were detected in traces in SCFM. MS/MS experiments 42 showed an increase of phospholipids derived from DOPC in SCFM-PC. We observed no 43 influence of the medium on the bacterial growth and a minor influence on the bacterial 44 shape. MIC values were generally higher in SCFM and SCFM-PC than in MHB.

Conclusions: We defined a *CF* sputum-like media which can be used for the membrane lipid
extraction of *P. aeruginosa*. We also showed that the growth medium does have an
influence on its membrane lipid composition and antibiotic resistance, especially for SCFMPC in which *P. aeruginosa* uses DOPC, in order to make its own membrane.

49 *General significance:* Our results show that considerable caution must be taken when 50 choosing a medium for lipid identification and antibiotic testing —especially for 51 phospholipids-enriched media.

52



56 Pseudomonas aeruginosa is an opportunistic pathogen bacterium which is a major 57 public health concern for its ability to survive on healthcare equipments [1]. This leads to nosocomial infections which are very difficult to eradicate. Due to its high pathogenicity for 58 immunocompromised patients, such as cystic fibrosis (CF) patients [2,3], P. aeruginosa is one 59 of the deadliest bacteria in hospitals. Moreover, P. aeruginosa can easily develop many 60 mechanisms of resistance against antibiotics [4], leading to most antibiotics becoming 61 useless. For these reasons, P. aeruginosa was set priority number one for the research and 62 development of new antibiotics and treatments, by the world health organization (WHO) [5]. 63

64 In order to develop new antibiotics, new targets and strategies are required. One of 65 the current new drug strategies involves targeting membrane phospholipids (e.g. cardiolipins [6]). Such new drugs could, by themselves, allow membrane lysis or could be 66 67 used in synergy to increase the effectiveness of antibiotics [7,8]. Previous analyses of the membrane lipid composition of *P. aeruginosa* were performed in culture media such as 68 minimal glucose medium (MGM) [9,10], Muller-Hilton broth (MHB) [11,12] or lysogeny broth 69 70 (LB) [13]. The membrane lipid composition mainly consisted of four lipid chemical classes: 71 phosphatidylethanolamines (PE), phosphatidylcholines (PC), phosphatidylglycérols (PG) [13] 72 and cardiolipins (CL) [12]. Moreover, these phospholipids were described to be constituted of saturated, unsaturated or cyclopropylated, fatty acyl chains ranging from C14 to C18 [10]. 73

74 Since P. aeruginosa is known to survive in diverse environments, by adapting its metabolism according to the available energy resources [14], an influence of the culture 75 medium on the membrane lipids should be expected. Due to the high pathogenicity of P. 76 77 aeruginosa in cases of CF lungs chronic infections, the CF lung sputum was chemically analysed with the purpose to reproduce it in laboratories [15]. This sputum was 78 79 characterized by specific amino acid concentrations, the presence of DNA, lipids and mucin and a high viscosity [16]. Thus, several media mimicking the CF sputum were described in 80 the literature [15-17]. The synthetic cystic fibrosis medium (SCFM) [15], first described, 81 contained amino acids, salts and sugars at adjusted concentrations, but lacked DNA, lipids 82 and mucin. This medium was then improved, as SCFM2, by the addition of DNA, lipids and 83 84 mucin [16].

12

Page 3 | 42

11

85 The Artificial Sputum medium (ASM) contained amino acids, mucin, DNA and egg yolk as a phospholipid nutrient [17]. However, most of these media are not compatible with 86 membrane lipid extraction, as the high viscosity of such media [16,17] does not allow 87 enough bacterial growth for exploitable quantities of lipid material. For this specific reason, 88 89 this work uses the commercial MHB as a reference medium and the SCFM one [15]. By adding phosphatidylcholine to SCFM (SCFM-PC), we also analysed the impact of this choline 90 nutrient source on the P. aeruginosa lipid composition. 1,2-dioleoyl-sn-glycero-3-91 phosphocholine (DOPC) was chosen in order to simulate the presence of lipids from 92 93 eukaryote cells, since DOPC is widely used for eukaryote cell modelling [18].

Herein, to our knowledge, this work reported, for the first time, the membrane phospholipid composition of *P. aeruginosa* grown in CF sputum-mimicking media -e.g.SCFM and SCFM-PC. The membrane lipids were identified and semi-quantified using liquid chromatography - mass spectrometry (LC-MS). Tandem mass spectrometry (MS/MS) experiments were performed to determine the fatty acyl composition of phospholipids. With the aim to link membrane lipid modifications and antibiotic resistance, the minimal inhibitory concentration (MIC) of four antibiotics was determined as well.

101

102 2. Material and methods

103 2.1 Chemicals

All SCFM components, chemicals required for the membrane lipid extraction and antibiotics were purchased from Sigma-Aldrich (Saint Quentin Fallavier, France). 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC), and phospholipids internal standards (PC 17:0/17:0, 0.5 μg; PE 17:0/17:0, 2.5 μg; PG 17:0/17:0, 1 μg; LPC 17:0, 1 μg; LPE 13:0, 2.5 μg; CL 14:0/14:0/14:0/14:0, 5 μg) were purchased from Avanti polar lipids (AL, USA). MHB media, brand Difco, was purchased from Fischer Scientific (UK). Milli Q grade water was obtained from an UltraClear TWF system (Evoqua water technologies, Germany).

111

Page 4 | 42

17

16

112 Methanol, chloroform, acetonitrile and isopropanol were purchased from Fischer Scientific 113 (UK), ammonium formate from Sigma-Aldrich (Saint Quentin Fallavier, France), formic acid 114 from Merck (Germany). Except methanol and chloroform which were HPLC grade, all 115 solvents and buffers used were LC-MS grade.

116

19

117 2.2. SCFM and SCFM-PC media preparation

The SCFM medium was first described by Palmer *et al.* [15]. In order to prepare this chemically defined medium more easily by hand, the number of individual stock solutions was reduced by mixing some of the individual stock solutions together (*e.g.* from 19 individual amino acids stock solutions to 6 individual or mixed amino acids stock solutions). Moreover, part of the medium was autoclaved.

123 The stock solutions were prepared from powder, using either autoclaved Milli-Q 124 grade water or NaOH solutions (concentrations will be detailed later) and stocked in the dark 125 at 4°C. The bottles used for the stock solutions were autoclaved as well.

A first stock solution was prepared by mixing the following thirteen amino acids, 126 whose final concentrations were: 360 mM alanine, 60 mM arginine -HCl, 40 mM cysteine -127 HCl, 300 mM glutamate -HCl, 240 mM glycine, 100 mM histidine -HCl, 420 mM lysine-HCl, 128 129 120 mM methionine, 140 mM ornithine -HCl, 340 mM proline, 280 mM serine, 200 mM threonine and 220 mM valine. A second stock solution was prepared by mixing isoleucine 130 131 and phenylalanine at 110 mM and 50 mM, respectively. Leucine was stocked at 100 mM. 132 Aspartate was stocked at 103 mM in 0.5 M NaOH. Tyrosine was stocked at 100 mM in 1 M NaOH. Tryptophan was stocked at 130 mM in 0.2 M NaOH. 133

The following salts were mixed into a single stock solution at these concentrations: 23 mM NH4Cl, 153 mM KCl, 511 mM NaCl, 13 mM NaH2PO4, 13 mM Na2HPO4, 3 mM K2SO4, 4 mM NaNO3. Morpholinepropanesulfonic acid (MOPS) was stocked at 100 mM. The mixed salts and the MOPS stock solution were then autoclave sterilised for storage purpose.

20

Page 5 | 42

138 CaCl2 and MgCl2 were mixed as a stock solution at 877 mM and 303 mM respectively. FeSO4 was stocked at 4 mM. D-glucose was stocked at 1 M. Sodium L-lactacte 139 140 was stocked at 10% w/w. CaCl2/MgCl2, Dglucose and Sodium L-lactacte stock solutions were filter sterilised through a 0.22-µm-pore-size filter. Since the FeSO4 stock solution could 141 142 neither be autoclaved (precipitation) nor filter sterilised (filter blockage), the FeSO4 powder was diluted into an autoclave sterilised bottle using autoclave sterilised Milli-Q water. Fresh 143 144 FeSO4 stock solution was systematically prepared to prevent precipitation during the storage. The full protocol for the preparation of the stock solutions for SCFM and SCFM-PC 145 medium is given in the Supplementary Information S1. 146

For 1 L of SCFM, the following volumes of stock solutions were added: 100 mL mixed salts, 25 mL MOPS, 805 mL Milli-Q water, 10 mL mixed amino acids (first solution), 10 mL isoleucine and phenylalanine (second solution), 16 mL leucine, 8 mL aspartate, 8 mL tyrosine, 0.1 mL tryptophan. The solution was then autoclave sterilised. After cooling to room temperature, the pH was adjusted to 6.5 using HCl 33% w/w. Finally, the following volumes of stock solutions were added: 2 mL CaCl2/MgCl2, 1 mL FeSO4, 3 mL D-glucose, 10.5 mL L-lactate.

154 The SCFM-PC medium preparation was based on the SCFM 2 developed by Turner et al. [16]. SCFM 2 is a modification of SCFM in which DOPC (PC 18:1 (9Z) / 18:1 (9Z)), DNA and 155 mucin are added. However, in our study, we had to develop SCFM-PC in which only DOPC 156 was added to SCFM. Indeed, when DNA and mucin are used, the extraction of membrane 157 lipids cannot be performed due to the high viscosity of the medium (unpublished work). The 158 SCFM-PC medium was prepared as the following: aliquots of DOPC stock solutions were 159 prepared in order to make different volumes of SCFM-PC with a final DOPC concentration of 160 100 μ g/mL, (aliquots of 10 mg, or 33 mg, to respectively prepare 100 mL, or 330 mL, of 161 SCFM-PC). The stock solutions of DOPC (250 mg/mL) were prepared in chloroform and were 162 stored under argon, in the dark and at -20 °C. The DOPC stock solution was slowly added to 163 the fresh SCFM medium by making it run along the inside of the Erlenmeyer flask —in order 164 to evaporate the chloroform as much as possible. Then, the solution was stirred until neither 165 traces nor lipid droplets could be seen anymore. Finally, in order to make sure that no traces 166

24

Page 6 | 42

23

167 of chloroform were left, the SCFM-PC medium was left to rest 30 min under a biosafety 168 cabinet.

169 The full protocol for the preparation of SCFM and SCFM-PC medium are given in the Supplementary Information S1. To verify that the autoclave sterilisation had not degraded 170 the amino acids (at the concentration of the medium and without adding sugars), SCFM 171 172 medium was checked using electrospray ionisation-mass spectrometry (ESI-MS) before and after sterilisation (for MS parameters, see Section 2.6). No difference was observed 173 suggesting that no degradation occurred. Growth curves of PAK into the autoclave sterilised 174 or filtered sterilised media were performed as well and showed no impact of the sterilisation 175 176 method on the growth of *P. aeruginosa*. MS spectra and growth curves are given in S2.

177

178 2.3. Bacterial strain, growth conditions and MICs determination

The *P. aeruginosa* strain PAK (PAK), used in this study, was obtained from Dr. 179 180 Lhousseine Touqui (Institut Pasteur, Paris, France). The P. aeruginosa PAK strain is known for 181 its high virulence, a high expression of pili and flagella, glycosylations and pathogenicity islands [19] and is commonly used in medical studies. PAK was stocked in Muller-Hinton 182 broth (MHB)/glycerol (70/30) at -80 °C. For growth kinetics, PAK was pre-cultured from this 183 stock solution, overnight at 37 °C in MHB, SCFM or SCFM-PC. This pre-culture was used to 184 inoculate 100 mL of MHB, SCFM or SCFM-PC (in a 250 mL Erlenmeyer flask) with 5.10⁵ colony 185 forming units (CFU)/mL. The culture was incubated at 37 °C for 24 h on a rotary shaker (140 186 rpm). Every hour for 8 h and at a final point of 24 h, OD₆₀₀ (optical density at 600 nm with 187 188 Cary 100 Bio spectrophotometer, Varian) was monitored and 100 µL of culture were collected for CFU numeration. For the MICs determination of carbenicillin, gentamicin, 189 ciprofloxacin, and colistin, the broth dilution method, in 96-well plates, was performed 190 191 according to Wiegand et al. [20], using an inoculum at OD₆₀₀ = 0.001. All these experiments were performed in biological triplicates for MHB, SCFM and SCFM-PC. 192

193

194

28

195

196

197 2.4. Atomic force microscopy (AFM) imaging

198 All glass substrates (glass cover for haemocytometer, 20x26mm, 0.4 mm thick, Hirschmann) were cut in 4 parts, cleaned with ethanol and dried. Using a 6-well plates, one 199 glass substrate was placed into each well and covered with 1 mL of MHB, SCFM or SCFM-PC. 200 201 A PAK preculture in either MHB, SCFM or SCFM-PC media (see Section 2.3) was used to inoculate each well at 10⁷ CFU/mL. In order to have enough attached bacteria, but with as 202 low as possible phenotype changes, the plate was incubated for 6 h at 37 °C, without any 203 204 mixing, and protected from light. A bacterial monolayer and irreversible attachment of the 205 biofilm could be achieved using this method. Then, the culture medium was removed using a Pasteur pipette. Each glass substrate was rinsed twice using water baths, carefully drained, 206 then dried overnight. 207

AFM imaging was performed with a Nanoscope 8 Multimode microscope (Bruker 208 Nano Surfaces, Santa Barbara, CA, USA) equipped with a 100 µm piezoelectric scanner. 209 Imaging was achieved in the air either using the contact mode (for bacteria length 210 measurements) or using the PeakForce[®] mode (for image presentation). In the contact 211 mode, the cantilevers used were characterized by a low spring constant of about 0.06 N/m 212 and were equipped with classical pyramidal Silicon Nitride tip. All the measurements were 213 214 performed with the feedback loop on. For the PeakForce[®] mode imaging, we used a soft Silicon Nitride cantilevers (spring constant of about 0.35 N/m) with sharp Silicon Nitride tip. 215 Images were obtained with a PeakForce Tapping frequency of 2kHz with the auto-amplitude 216 on. Average force applied during scanning was 5 nN. 217

218

219 2.5. Membrane lipid extraction

The membrane lipid extraction of PAK was performed as described by Deschamps *et* al. [12]. Briefly, from a pre-culture overnight (see Section 2.3), PAK was grown for 7 h in

32

Page 8 | 42

222 MHB, SCFM or SCFM-PC (5.10^5 CFU/mL for initial inoculum) and a pellet was collected by 223 centrifugation.

Then, alginate lysis was performed using alginate lyase in PBS (0.15 mg/mL), followed by sonication, centrifugation and ultracentrifugation. Finally, lipids were extracted using a modified version of the Bligh and Dyer protocol [21]. In the present work, the liquid-liquid extraction was modified with the addition of internal standards as followed:

For a pellet of 20 mg, 500 µL of milli-Q water was added to resuspend the pellet and 228 then vortex-mixed for 5 min. 1.2 mL of methanol was added and then vortex-mixed for 15 229 min, to degrade proteolipids. Then, the mixture was centrifuged (4000 $\times q$, 10 min, 22 °C) and 230 231 the liquid phase recovered. After adding 0.6 mL of chloroform spiked with phospholipid standards (PC 17:0/17:0, 0.5 μg; PE 17:0/17:0, 2.5 μg; PG 17:0/17:0, 1 μg; CL 232 14:0/14:0/14:0, 5 μg), the solution was vortex mixed for 15 min and sonicated for 15 233 min. 0.6 mL of chloroform was added, then the solution was vortex mixed for another 15 234 min. 0.62 mL of 1 M ammonium acetate was added and the solution was vortex-mixed for 235 15 min. Finally, the mixture was left to rest for 30 min. One milliliter of the organic phase 236 237 was recovered and 0.94 mL of chloroform was added to the aqueous phase for a second liquid-liquid extraction. After vortex mixing for 15 min, the mixture was left to rest again for 238 30 min. The aqueous phase was removed and organic phases were pooled together and 239 evaporated under argon. Lipid extracts were conserved under argon at -20 °C. For other 240 samples pellet masses, solvent volumes and standard masses were adjusted proportionally. 241 This extraction was performed in biological triplicate. 242

243

244 2.6. Liquid chromatography - mass spectrometry (LC-MS) analysis

The sample preparation for LC-MS analyses, the MS and LC parameters —including LC gradient— were as described by Deschamps *et al.* [12]. Briefly, the dried lipids extracts were re-constituted into 50 μ L of chloroform/methanol (2/1, v/v) and 1/5 diluted into isopropanol/ acetonitrile/water (4/3/1, v/v).

249

36

251 The LC-MS experiments were performed using an UHPLC system (Dionex Ultimate 3000 RSLC, Thermo Scientific, San Jose, CA, USA) coupled to a hybrid quadrupole time-of-flight 252 with an ion mobility cell instrument (Q-IMS-TOF, SYNAPT G2 HDMS, Waters MS 253 Technologies, Manchester, UK) equipped with an electrospray ionisation source. LC -MS data 254 255 were acquired in triplicate in positive and negative ion modes.

The column used was a 1.0×100 mm, Acquity UPLC CSH C18 1.7 μ m column (Waters, 256 Manchester, UK) equipped with a 0.2 µm prefilter. Mobile phase A consisted of 257 acetonitrile/aqueous 10 mM ammonium formate (60/40) + 0.1% formic acid and mobile 258 259 phase B consisted of isopropanol/acetonitrile/aqueous 10 mM ammonium formate (88/8/4) + 0.1% formic acid. Data acquisition was performed using MassLynx 4.1 (Waters, 260 Manchester, UK). 261

Data processing, automatic identification and integration of peaks were performed 262 using UNIFI 1.8.2.169 (Waters, Manchester, UK). Relative areas were calculated by dividing 263 the area of the identified phospholipids by the area of the standard from the corresponding 264

class of phospholipids (*e.g. relative area* = $\frac{Area of PE 34:1}{Area of PE 17:0/17:0}$). Areas were automatically 265 266 calculated, from the extracted ion chromatograms, using the monoisotopic peak of [M+H]⁺ 267 or [M–H]⁻ ions, for positive or negative ionisation respectively. The monoisotopic peak was used, instead of the sum of all isotopes, since not all isotopes could be observed for 268 phospholipids at small concentrations (e.g. CL 67:3). We also selected only protonated or 269 270 deprotonated species, instead of the sum of all detected adducts (i.e. [M+Na]⁺, [M+NH₄]⁺, [M+CH₃COO]⁻) for similar reasons. The standard deviation and relative standard deviation of 271 272 the relative area (the number of replicates (n) in which the phospholipids were identified were; $7 \le n \le 9$ for PE, PC and PG, $3 \le n \le 6$ for CL) were calculated to plot error bars and to check 273 the repeatability of the measurements. Anova tests and Turkey mean comparisons were 274 performed using OriginPro 2016 (64-bit) b9.3.226. 275

MS/MS experiments were performed in biological triplicate, using the parameters 276 previously described [12]. 277 40

Page 10 | 42

250

39

278

MS/MS experiments were performed in negative ion mode using a collision energy ramp from 25 eV to 45 eV. For PE (*i.e.* PE 32:1, PE 34:1, PE 36:2) and PG species (*i.e.* PG 32:1, PG 34:1, PG 36:2), the ion selected in the quadrupole was the $[M-H]^-$, whereas for PC species (*i.e.* PC 32:1, PC 34:1, PC 36:2), the ion selected was the $[M+HCO_2]^-$. MS/MS spectra were processed using MassLynx 4.1 (Waters).

284

285 3. Results

286 3.1. Impact of the medium composition on the growth and MIC determination

The growth curves of PAK grown in MHB, SCFM or SCFM-PC are given in Fig. 1. 287 Measurements of OD₆₀₀ (Fig. 1.A) or CFU/ mL (Fig. 1.B) as a function of time showed a similar 288 growth of PAK in the three media. This observation included no lag phase time, an 289 290 exponential phase time of approximately 8 h and a doubling time of 43, 42 or 44 minutes in MHB, SCFM or SCFM-PC, respectively. As a matter of fact, using these growth curves, the 291 growth time for the lipid extraction (7h) was chosen as it corresponds to the end of the 292 exponential phase. Thus, exploitable quantities of bacteria could be collected without risking 293 a lack of nutrients. 294

295





Fig. 1. Growth curves of PAK strain in MHB, SCFM and SCFM-PC. black circles for MHB, red squares for SCFM, blue
 diamonds for SCFM-PC. A. optical density (OD) plotted against time. B. Colony Forming Unit (CFU)/ mL plotted against time.
 Error bars: standard deviation.

Page 11 | 42

44

AFM images (Fig. 2. A, B, C) show similar bacterial shapes for all media. For MHB and SCFM, the average lengths (2.8 μ m ± 0.7 μ m) of PAK were equivalent. However, when PAK was grown in SCFM-PC, the average length was a little smaller (2.6 μ m ± 0.6 μ m), but as a counterpart, the height was higher (Fig.2.C), showing that PAK seemed to spread less on the surface than in the other media. Interestingly, as contrary to the other two media, colonies of PAK grown in SCFM-PC showed bacteria were not glued to each other, probably due to the presence of DOPC in the growth medium.



Page 12 | 42

Fig. 1. AFM images of PAK young biofilms grown on glass substrates. Images are shown as topographic images overlaid
with a local contrast image (Kernel size: 2; blending depth: 2; weight: 1). Classical filters as flattening and 3-points levelling
were applied to the topographic image using the Gwyddion software (http://www.gwyddion.net). A. PAK grown in MHB; B.
PAK grown in SCFM; C. PAK grown in SCFM-PC.

The MIC values of four antibiotics (carbenicillin, gentamicin, ciprofloxacin, colistin) for 313 PAK grown in MHB, SCFM or SCFM-PC are given in Table 1. Susceptibility (S) or resistance (R) 314 to the antibiotic were given according to the norm Eucast SFM 2019. In fact, a two-fold MIC 315 difference cannot be considered significant, since the experiment error is of one dilution (for 316 the protocol, see 2.4). Consequently, the influence of the medium on the MIC values could 317 significantly be noted for carbenicillin, gentamicin and colistin, but not for ciprofloxacin. The 318 MIC of gentamicin and colistin were higher when grown in SCFM or SCFM-PC rather than 319 into MHB. Moreover, a switch from susceptibility to resistance could be observed for colistin 320 321 and gentamicin, depending on the medium of growth. Surprisingly, the MIC of carbenicillin was much smaller when PAK was grown in SCFM rather than in MHB, but was identical 322 between MHB and SCFM-PC media. 323

324

Table 1. Minimal inhibitory concentrations (MIC) for PAK strain. (S) for susceptibility of PAK to the antibiotic,
 (R) for resistance. Both (S) and (R) are given according to the norm Eucast SFM 2019 —apart for carbenicillin for
 which reference values was not given in the norm.

medium/	carbenicillin	gentamicin	ciprofloxacin	colistin	
antibiotic	antibiotic (MIC		in μg/mL)		
МНВ	64-128	0.5 (S)	0.125 (S)	0.125-0.25 (S)	
SCFM	16	4-8 (R)	0.125 (S)	2-4 (R)	
SCFM-PC	64-128	4-8 (R)	0.25 (S)	2 (R)	

328

329 **3.2** Comparison of the membrane phospholipids composition


330 3.2.1 Semi-quantification

The membrane lipids of PAK were identified using a home-made retention time-*m/z* library, which was previously described for PAK grown in MHB [12]. Lipid annotation was P a g e 13 | 42 based on the nomenclature of Liebisch *et al.* [22]. Forty-two lipids were identified. Twenty
phospholipids were identified using positive ionisation: 7 phosphatidylcholines (PC) and 13
cardiolipins (CL).

Twenty-two were identified using negative ion mode: 13 phosphatidylethanolamines (PE) and 9 phosphatidylglycerols (PG). Please note that PE and CL could be observed in both positive and negative ion modes. However, using our analytical conditions (especially the LC mobile phase with buffers), a higher signal was observed in positive ionisation mode for CL and in negative ionisation mode for PE.

When PAK grown in SCFM or SCFM-PC, no new phospholipids were detected. Therefore, a semi-quantitative approach was used in order to highlight the influence of the medium. Please note that, while PC 34:0, PE 34:0 and PG 34:0 were detected as traces in the membrane of PAK, the relative area of these phospholipids could not be determined. Actually, using our chromatographic conditions, these phospholipids could not be separated from the standards (*i.e.* PC 17:0/17:0, PE 17:0/17:0, PG 17:0/17:0), therefore, the PC 34:0, PE 34:0 and PG 34:0 produced by PAK were excluded from the study.

Fig. 3.A., 3.B. and 3.C. show relative areas of some depictive examples of the membrane phospholipids extracted from PAK grown in MHB, SCFM or SCFM-PC media. The relative areas for all the identified phospholipids are given in S2 (Fig S2.4 to S2.7).



Page 14 | 42

55

56

351

Fig. 2. Relative areas of phospholipids extracted from PAK. $Relative area = \frac{PARPL dred}{PL standard area}$. Black bars: PAK grown in MHB, red bars: PAK grown in SCFM, blue bars: PAK grown in SCFM-PC. Error bars: standard deviation (7≤n≤9 for PE, PC and PG, 3≤n≤6 for CL). P-values are reported —between MHB and SCFM. SCFM and SCFM-PC and MHB and SCFM-PC as: * for p<0.05, ** for p<0.01, *** for p<0.001, ns for non-significant. A. PC less or equally produced in SCFM-PC than MHB and mostly not produced in SCFM; B. phospholipids more produced in MHB than SCFM or SCFM-PC; C. phospholipids more produced in SCFM-PC than SCFM or MHB.

PAK PL area

358 Depending on the medium of growth, three trends of relative areas could be observed. As shown in Fig. 3.A., apart from PC 34:1 and PC 36:2 (Fig. 3.C.), PC were significantly less 359 produced for PAK grown in SCFM rather than MHB or SCFM-PC. As shown in Fig. 3.B. and S2 360 (Fig S2.4 to S2.7), most phospholipids (23) were more produced in MHB than SCFM or SCFM-361 PC. As shown in Fig. 3.C., phospholipids containing oleic acid (C18:1) were greatly over-362 produced in SCFM-PC, especially for PE 34:1, PC 34:1, PG 34:1 and PE 36:2, PC 36:2, PG 36:2. 363 364 Caution must be taken regarding the high relative area of PC 36:2 extracted from PAK grown 365 in SCFM-PC. Indeed, this may be due to i) direct incorporation of DOPC inside the bacteria membrane —without any modifications, ii) contamination of our samples with the culture 366 medium DOPC or iii) both of i) and ii). However, it is clear from the over-production of PE 367 36:2, PG 36:2 and phospholipids containing oleic acid, that DOPC is at least recycled by the 368 bacteria to produce phospholipids. Then, the presence of DOPC directly incorporated into 369 the bacteria membrane would be a very likely hypothesis. 370

371

372 3.2.2 Fatty acid composition

In order to evaluate the influence of the growth medium on the fatty acid 373 composition, MS/MS experiments were performed, on the most intense phospholipids, in 374 375 biological triplicates and for each medium. Fragment identification was performed using phospholipid fragments described in the literature [23,24]. S3 gives all the fatty acid 376 fragments of interest in negative ion mode —carboxylate anions R₁COO⁻⁻ for PC/PE/PG 377 32:1, 34:1 and 36:2. Please note that for SCFM medium, PC species could not be detected in 378 negative ion mode, since they were only produced as traces in this medium (see 3.2.1) and 379 PC are known to not ionize well in negative ion mode, even with the $[M+HCO_2]^-$ adduct. 380

60

Page 15 | 42

59

As previously described by *Hsu et al.* [23], the loss of the fatty acid in the sn-2 position is favoured. Hence, in order to compare the proportion of the two sn-1/2 position isomers (*e.g.* PG 16:0/16:1 and PG 16:1/16:0) between the three media, the following ratio

was calculated $ratio 1 = \frac{Intensity fatty acid sn - 1}{Intensity fatty acid sn - 2}$. When several isomers of fatty acyl chain length (*e.g.* PE 16:0/16:1 and PE 14:0/18:1) were observed, the following ratio was calculated:

ratio $2 = \frac{Intensity fatty acid sn - 2 of isomer 2}{Intensity fatty acid sn - 2 of isomer 1}$. The ratio 2 was calculated using only the sn-2 fatty acid since the sn-1 fatty acid of the second isomer (less abundant) was not detected for all phospholipids. Fig 4. shows the MS/MS spectra obtained for PG 34:1 in the three media (A. MHB, B. SCFM, C. SCFM-PC) and illustrates the determination of the ratio 1. The sn-2 fatty acid of isomer 2 (C16:1) was also given to illustrate the abundance difference between isomer 1 and isomer 2. The sn-1 fatty acid of isomer 2 (C18:0) was not detected. All calculated ratios means, standard deviation and relative standard deviation, are given in S3.

Page 16 | 42

65 66






Fig. 4 MSMS Spectra of [PG 34:1-H]⁻ and determination of the ratio 1. Ratio 1 allows to compare the proportion of the two sn-1/2 position isomers $\left(ratio 1 = \frac{Intensity fatty acid sn-1}{Intensity fatty acid sn-2}\right)$ between the three media. Bracket values: ion intensities. **A.** PAK grown in MHB; **B.** PAK grown in SCFM; **C.** PAK grown in SCFM-PC.

Table 2 shows the major isomers identified for PC 32:1, PE 32:1, PG 32:1, PC 34:1, PE 34:1 and PG 34:1. The major isomer was identical in MHB and SCFM media. However, when compared to MHB and SCFM, the SCFM-PC medium shows different isomers for two phospholipids: PC 32:1 and PG 34:1. In SCFM-PC, the major isomer was PC 14:0/18:1 for PC 32:1 (PC 16:0/16:1 in MHB), and PG 16:0/18:1 for PG 34:1 (PG 18:1/16:0 in MHB or SCFM). Regarding sn-1/2 position isomers, for PG 32:1, PC 34:1/ PE 34:1/ PG 34:1, the respective

68

16:1/16:0 and 16:0/18:1 isomers were significantly more produced in SCFM-PC than in SCFM
or in MHB (ratio values in S3).

406

407 Table 2. Fatty acid composition of the major isomer for six phospholipids, depending on the medium of 408 growth.

	PC 32:1	PE 32:1	PG 32:1	PC 34:1	PE 34:1	PG 34:1
МНВ	16:0/16:1	16:0/16:1	16:0/16:1	18:1/16:0	18:1/16:0	18:1/16:0
SCFM	nd	16:0/16:1	16:0/16:1	nd	18:1/16:0	18:1/16:0
SCFM-PC	14:0/18:1	16:0/16:1	16:0/16:1*	18:1/16:0*	18:1/16:0*	16:0/18:1

nd: not detected; * for PG 32:1, PC 34:1 and PE 34:1, the respective 16:1/16:0, 16:0/18:1 and 16:0/18:1 isomers were significantly more produced in SCFM-PC than in SCFM or in MHB.

409

Regarding PC/PE/PG 36:2 (see S3), the major isomers were PC/PE/PG 18:1/18:1 for all media. However, whereas no other isomer could be observed for PC 36:2 in any media, other isomers were observed for PE 36:2 and PG 36:2. For PE 36:2, PE 19:1/17:1 was detected, in trace level, in MHB (ratio 2 = 0.07 ± 0.02), SCFM (ratio 2 = 0.05 ± 0.02) and SCFM-PC (ratio 2 = 0.01 ± 0.01). For PG 36:2, PG 20:1/16:1 was observed in MHB (ratio 2 = 0.55 ± 0.09), SCFM (ratio 2 = 0.52 ± 0.19) and in trace level in SCFM-PC (ratio 2 = 0.04 ± 0.01).

416

417

418

419 4. Discussion

To our knowledge, this is the first study to analyse the membrane lipid composition of *P. aeruginosa* in CF sputum-like media (*e.g.* SCFM and SCFM-PC) and compare it with a classical medium. The three following media were used: the commercial MHB —as a

72

Page 18 | 42

reference medium, SCFM [15] and a modified version of SCFM by the addition of aphosphatidylcholine (SCFM-PC).

425 When studying the influence of the culture medium on the production of molecules by bacteria, checking that the bacterial growth is not affected by the culture medium is 426 crucial. Here, growth curves (see 3.1) showed that the growth of PAK was identical when 427 428 grown in MHB, SCFM or SCFM-PC. As detailed in the protocol of the membrane lipid extraction (see 2.5), the culture was stopped at the same time for every medium (end of the 429 430 exponential phase, see 3.1). Therefore, the following discussion could be made assuming that the membrane lipid composition modifications were not linked to a difference in the 431 432 bacterium growth phase. This should be noted as a recent work by Le Sénéchal et al. [13] showed that the phospholipid content of P. aeruginosa PAO1 was closely related to the 433 bacterial growth. 434

Before going further into the discussion, one should note that a plausible criticism of our 435 methodology is that *P. aeruginosa* was grown in planktonic conditions instead of biofilm 436 437 conditions, which should better reproduce the CF sputum growth conditions. However, since laboratory biofilm are grown on abiotic sterile surfaces, the adherence of the biofilm is likely 438 439 to differ from the one in CF sputum, leading to possible lipid modifications. Moreover, many 440 studies on clinical P. aeruginosa were performed in shaken flasks since even the sampling of the bacterium would be enough to alter its metabolic phenotype [25]. Despite these 441 limitations, we believe that SCFM-PC is a good compromise medium for rigorous analysis of 442 443 the membrane lipids of *P. aeruginosa*.

The main focus of this study was to investigate the influence of the medium on the phospholipids composition of the membrane. Using LC-MS in qualitative manner, as a first approach, we could not observe any influence of the medium on the type of identified phospholipids.

Therefore, a semi-quantification approach (comparison of relative intensities, using internal
standards) was used (see 3.2.1). The most remarkable result was that most phospholipids
were less produced into SCFM, compared to MHB. Knowing that lipids could be found in CFsputum [26], SCFM-PC was made, by adding DOPC to SCFM, in order to avoid the lack of PC
P a g e 19 | 42

75

452 species. When PAK was grown in SCFM-PC, we could see the increase of the phospholipids 453 with the longest fatty acyl chains (see Fig. 3.C). This increase might counterbalance the shortage of other lipids. However, for SCFM, we haven't identified any new phospholipids 454 nor increase of other phospholipids. Ornithine-lipids, which were described to be produced 455 by *P. aeruginosa* when grown in phosphate limiting conditions [27], were not detected. Two 456 hypothesis can be assumed regarding the decrease of phospholipids of PAK grown in SCFM: 457 458 i) novel phospholipids species were produced, but were neither extracted using our extraction conditions (see 2.6), nor detected using our analytical conditions (see 2.7), ii) the 459 460 lipid-protein ratio, which is supposed to be around 1/1 (w/w) for bacteria [28], was modified. The hypothesis that PAK grown in SCFM could be smaller than grown in MHB —leading to an 461 overall lighter weight of phospholipids— was also considered. However, as shown by the 462 AFM images in Fig. 2. (see 3.1), no significant influence of the medium on size nor on the 463 464 shape of PAK was observed, consequently this hypothesis was rejected.

MS/MS experiments were performed, as well, in order to evaluate the influence of 465 the growth medium on the fatty acid composition of phospholipids (see 3.2.2). The most 466 467 remarkable observation was that the fatty acid C18:1 was strikingly more abundant in 468 phospholipids produced by PAK grown in SCFM-PC than SCFM or MHB. This resulted into an inversion of the most abundant isomer for PC 32:1 and PG 34:1 (from MHB or SCFM to 469 SCFM-PC). Indeed, for PC 32:1, both PC 14:0/18:1 and PC 16:0/16:1 were detected into MHB 470 and SCFM-PC, but for SCFM-PC the major isomer was PC 14:0/18:1, whereas for MHB, the 471 major isomer was PC 16:0/16:1. Also, for PG 34:1, the major isomer was PG 16:0/18:1 in the 472 case of SCFM-PC, whereas for MHB or SCFM, the major isomer was PG 18:1/16:0. Moreover, 473 474 isomers containing C 18:1 in sn-2 position were favoured when PAK was grown in SCFM-PC. 475 Regarding PG 32:1, PC 34:1 and PE 34:1, the respective 16:1/16:0, 16:0/18:1 and 16:0/18:1 isomers were significantly more produced in SCFM-PC than in SCFM or in MHB. 476

The most likely explanation for these observations would be that *P. aeruginosa* would take DOPC from the SCFM-PC, and modify it, in order to produce its own phospholipids, as previously described for polyunsaturated fatty acids [29]. As a matter of fact, this hypothesis can also be supported by the overproduction of PE 36:2 and PG 36:2 (see Fig. 3.C. in part

80

81 82 Page 20 | 42

481 3.2.1) in SCFM-PC. Indeed, in most bacteria, PC are synthesised from PE, while PG are 482 synthesised using another pathway [30]. However, in the case of P. aeruginosa, it was 483 demonstrated that PC are synthesised from a phosphatidic acid (PA) and a choline [31]. Therefore, PC, PE and PG are synthesised from three different pathways which uses PA as a 484 common precursor. Thus, PA 36:2, recycled from DOPC, is likely used to synthesise PE 36:2 485 and PG 36:2. Consequently, these modifications would include: i) change of the polar head 486 group and ii) replacement of the sn-1 fatty acid. Since adding a phospholipid to the growth 487 medium had an influence on the membrane phospholipids of *P. aeruginosa*, we should note 488 489 that caution must be taken when choosing this phospholipid, in regards to the aim of the study. 490

Finally, as described in 3.4.1, the other less abundant isomer of PE 36:2 (*i.e.* PE 19:1/17:1) and PG 36:2 (*i.e.* PG 20:1/16:1) were produced for MHB and SCFM, but only in traces for SCFM-PC. Taking into account these observations and the inversion of the major isomer previously described, one should note that caution must be taken when analysing the fatty acid composition of phospholipids. Our results show that for an identical fatty acyl chain length, the fatty acid composition might not be the same for different polar heads (*e.g.* PC 32:1, PE 32:1 and PG 32:1).

498 In a second approach, the MIC values of four antibiotics were determined (see 3.1) 499 with the aim to link membrane lipids modifications and antibiotic resistance. Indeed, the antibiotic susceptibility of *P. aeruginosa* is related to its ability to guarantee membrane 500 homeostasis — maintenance of the membrane physical properties [32]. This homeostasis can 501 502 happen by modifying phospholipids in different ways. The stability of the membrane and, accordingly, the decrease of the permeability, can be enhanced by increasing the fatty acyl 503 504 chain length [33]. Conversely, the fluidity and permeability can be increased by introducing a 505 double bond or a cyclopropyl (more stable to acidic conditions than a double bond), or a terminally branched methyl on the fatty acyl chain [34]. 506

The ratio of negatively charged phospholipids (CL and PG) and neutral (PE) or positively charged phospholipids (PC) can also be modified in order to make the membrane less sensitive to pH or to the medium ion composition [35]. The replacement of PE by PC was Page 21 | 42

85 86

also described to enhance the membrane stability due to the ability of PC to form bilayersmore easily than PE [33].

512 As described in 3.4.1., PAK was found to produce less PC species when grown in SCFM than into MHB. MIC values of carbenicillin were also seemingly smaller when PAK was grown in 513 SCFM (MIC_{SCFM} = 16 μ g/mL) than in MHB (MIC_{MHB} = 64-128 μ g/mL). Carbenicillin mechanism 514 515 of action consists in inhibiting the synthesis of the bacterial cell-wall peptidoglycan. Also, since carbenicillin is an hydrophobic antibiotic (logP = 1.13 [36]), we may assume that this 516 antibiotic can cross the lipid membrane instead of going through the porins. Hence, we can 517 make the hypothesis that PAK, when grown in SCFM, was more susceptible to carbenicillin 518 519 because the membrane cell was less stable due to the lack of PC species. Then, when DOPC was added to the SCFM medium, the presence of PC in the membrane restore a 520 521 susceptibility to carbenicillin similar to the one in MHB (MIC_{MHB} = MIC_{SCFM-PC}).

522 Regarding the other antibiotics tested, the influence of the growth medium on the MIC values was observed for colistin and gentamicin, but not for ciprofloxacin (see 3.1). It is 523 524 notable that, MIC values of gentamicin, colistin and ciprofloxacin in SCFM were in agreement 525 with those from Pusic et al. [37] SCFM medium). We also observed an increase of MIC values 526 from a rich medium (MHB) to the chemically defined SCFM (see Table 1). This observation was also described by Pusic et al. (from LB to SCFM), and for colistin between MHB and ASM, 527 by Diaz Iglesias et al. [38]. In SCFM-PC, the MIC values of colistin and gentamicin were equal 528 to the ones in SCFM. Therefore, the link between the membrane stability (decrease of the 529 membrane stability in SCFM but restored in SCFM-PC) and the MIC, described for 530 carbenicillin, might not be suitable for other antibiotics. The membrane permeability 531 changes, induced by the growth medium, may partly explain P. aeruginosa antibiotic 532 susceptibility modifications. Actually, it is rather a multi-factor issue since the nutrients 533 534 present in the growth medium can induce particular resistance mechanisms of *P. aeruginosa* [26]. 535

- 536
- 537
- 88

Page 22 | 42

538 **5. Conclusion**

539 In this study, we reported the membrane lipid composition of *P. aeruginosa* grown into CF sputum-mimicking media (SCFM and SCFM-PC). We showed that the growth medium 540 541 had an influence on the phospholipid quantities. We observed that PC species were produced in trace level in SCFM. Implementing DOPC to SCFM (SCFM-PC medium), as a 542 543 choline nutrient, not only had an influence on the quantities of PC species, but also on the length of the fatty acids parts of the phospholipids and phospholipid isomerism. Such 544 modifications may affect the membrane permeability. Actually, MIC variations of the 545 hydrophobic carbenicillin antibiotic support this hypothesis. These results suggest that the 546 membrane lipid composition should be taken into account for antibiotic susceptibility 547 testing. Since we showed that the growth medium can influence the membrane lipid 548 549 composition, caution must be taken when choosing a medium, especially for clinical studies.

550

551 Conflict of interest

552 The authors declare that they have neither conflict of interest nor competing financial 553 interest.

554

555 Funding information

556 The authors gratefully acknowledge European Regional Development Fund (ERDF, no. 557 HN0001343), Labex SynOrg (ANR-11-LABX-0029) and Région Normandie for their financial 558 support.

559

92

560 **REFERENCES**

561 [1] P. Pachori, R. Gothalwal, P. Gandhi, Emergence of antibiotic resistance *Pseudomonas aeruginosa* in intensive 562 care unit; a critical review, Genes Dis., 6 (2019) 109-119.

563 [2] W.D. Smith, E. Bardin, L. Cameron, C.L. Edmondson, K.V. Farrant, I. Martin, R.A. Murphy, O. Soren, A.R.

- Turnbull, N. Wierre-Gore, E.W. Alton, J.G. Bundy, A. Bush, G.J. Connett, S.N. Faust, A. Filloux, P.S. Freemont, A.L.
 Jones, Z. Takats, J.S. Webb, H.D. Williams, J.C. Davies, Current and future therapies for *Pseudomonas aeruginosa*infection in patients with cystic fibrosis, FEMS microbiology letters, 364 (2017).
- 567 [3] R.T. Sadikot, T.S. Blackwell, J.W. Christman, A.S. Prince, Pathogen-host interactions in *Pseudomonas* 568 *aeruginosa* pneumonia, American journal of respiratory and critical care medicine, 171 (2005) 1209-1223.
- 569 [4] M. Bassetti, A. Vena, A. Croxatto, E. Righi, B. Guery, How to manage *Pseudomonas aeruginosa* infections, 570 Drugs Context, 7 (2018) 212527.
- 571 [5] E. Tacconelli, *et al.* Discovery, research, and development of new antibiotics: the WHO priority list of 572 antibiotic-resistant bacteria and tuberculosis, The Lancet Infectious Diseases, 18 (2018) 318-327.
- 573 [6] M. El Khoury, J. Swain, G. Sautrey, L. Zimmermann, P. Van Der Smissen, J.-L. Décout, M.-P. Mingeot-Leclercq,
 574 Targeting Bacterial Cardiolipin Enriched Microdomains: An Antimicrobial Strategy Used by Amphiphilic
 575 Aminoglycoside Antibiotics, Sci. Rep., 7 (2017).
- 576 [7] P.V. Escriba, Membrane-lipid therapy: a new approach in molecular medicine, Trends Mol Med, 12 (2006) 34577 43.
- 578 [8] R.M. Epand, C. Walker, R.F. Epand, N.A. Magarvey, Molecular mechanisms of membrane targeting 579 antibiotics, Biochim Biophys Acta, 1858 (2016) 980-987.
- [9] H. Benamara, C. Rihouey, T. Jouenne, S. Alexandre, Impact of the biofilm mode of growth on the inner
 membrane phospholipid composition and lipid domains in *Pseudomonas aeruginosa*, Biochim Biophys Acta,
 1808 (2011) 98-105.
- 583 [10] H. Benamara, C. Rihouey, I. Abbes, M.A. Ben Mlouka, J. Hardouin, T. Jouenne, S. Alexandre, 584 Characterization of membrane lipidome changes in *Pseudomonas aeruginosa* during biofilm growth on glass 585 wool, PLoS One, 9 (2014) 9.
- [11] I. Abbes, C. Rihouey, J. Hardouin, T. Jouenne, E. De, S. Alexandre, Identification by mass spectrometry of
 glucosaminylphosphatidylglycerol, a phosphatidylglycerol derivative, produced by *Pseudomonas aeruginosa*,
 Rapid communications in mass spectrometry : RCM, 32 (2018) 2113-2121.
- 589 [12] E. Deschamps, I. Schmitz-Afonso, A. Schaumann, E. De, C. Loutelier-Bourhis, S. Alexandre, C. Afonso,
 590 Determination of the collision cross sections of cardiolipins and phospholipids from *Pseudomonas aeruginosa*591 by traveling wave ion mobility spectrometry-mass spectrometry using a novel correction strategy, Anal. Bioanal.
 592 Chem., 411 (2019) 8123-8131.
- [13] C. Le Senechal, M. Crouzet, P. Costaglioli, C. Barthe, C. Bure, S. Vilain, Phospholipid Content of
 Pseudomonas aeruginosa PAO1 Is Modulated by the Growth Phase Rather Than the Immobilization State,
 Lipids, 54 (2019) 519-529.
- 596 [14] M.A. Oberhardt, J. Puchalka, K.E. Fryer, V.A. Martins dos Santos, J.A. Papin, Genome-scale metabolic
 597 network analysis of the opportunistic pathogen *Pseudomonas aeruginosa* PAO1, J Bacteriol, 190 (2008) 2790598 2803.
- 599 [15] K.L. Palmer, L.M. Aye, M. Whiteley, Nutritional cues control *Pseudomonas aeruginosa* multicellular 600 behavior in cystic fibrosis sputum, Journal of bacteriology, 189 (2007) 8079-8087.

96

Page 24 | 42

- 601 [16] K.H. Turner, A.K. Wessel, G.C. Palmer, J.L. Murray, M. Whiteley, Essential genome of *Pseudomonas* 602 *aeruginosa* in cystic fibrosis sputum, Proc. Natl. Acad. Sci. U.S.A, 112 (2015) 4110-4115.
- 603 [17] S. Kirchner, J.L. Fothergill, E.A. Wright, C.E. James, E. Mowat, C. Winstanley, Use of artificial sputum 604 medium to test antibiotic efficacy against *Pseudomonas aeruginosa* in conditions more relevant to the cystic 605 fibrosis lung, Journal of visualized experiments : JoVE, (2012) e3857.
- [18] J. Zhao, J. Wu, F.A. Heberle, T.T. Mills, P. Klawitter, G. Huang, G. Costanza, G.W. Feigenson, Phase studies of
 model biomembranes: complex behavior of DSPC/DOPC/cholesterol, Biochim Biophys Acta, 1768 (2007) 27642776.
- [19] A.K. Cain, L.M. Nolan, G.J. Sullivan, C.B. Whitchurch, A. Filloux, J. Parkhill, Complete Genome Sequence of
 Pseudomonas aeruginosa Reference Strain PAK, Microbiology Resource Announcements, 8 (2019) e00865 00819.
- [20] I. Wiegand, K. Hilpert, R.E. Hancock, Agar and broth dilution methods to determine the minimal inhibitoryconcentration (MIC) of antimicrobial substances, Nat Protoc, 3 (2008) 163-175.
- 614 [21] E.G. Bligh, W.J. Dyer, A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION, Canadian Journal615 of Biochemistry and Physiology, 37 (1959).
- 616 [22] G. Liebisch, J.A. Vizcaino, H. Kofeler, M. Trotzmuller, W.J. Griffiths, G. Schmitz, F. Spener, M.J. Wakelam,
 617 Shorthand notation for lipid structures derived from mass spectrometry, Journal of lipid research, 54 (2013)
 618 1523-1530.
- [23] F.-F. Hsu, J. Turk, Electrospray Ionization with Low-energy Collisionally Activated Dissociation Tandem Mass
 Spectrometry of Glycerophospholipids: Mechanisms of Fragmentation and Structural Characterization, J.
 Chromatogr. B Analyt. Technol. Biomed. Life Sci., 877 (2009) 22.
- 622 [24] B. Colsch, F. Fenaille, A. Warnet, C. Junot, J.C. Tabet, Mechanisms governing the fragmentation of
 623 glycerophospholipids containing choline and ethanolamine polar head groups, European journal of mass
 624 spectrometry, 23 (2017) 427-444.
- 625 [25] W.M. van Gulik, Fast sampling for quantitative microbial metabolomics, Current opinion in biotechnology, 626 21 (2010) 27-34.
- [26] M.S. Son, W.J. Matthews, Jr., Y. Kang, D.T. Nguyen, T.T. Hoang, In vivo evidence of *Pseudomonas aeruginosa*nutrient acquisition and pathogenesis in the lungs of cystic fibrosis patients, Infection and immunity, 75 (2007)
 5313-5324.
- [27] S. Lewenza, R. Falsafi, M. Bains, P. Rohs, J. Stupak, G.D. Sprott, R.E.W. Hancock, The olsA gene mediates the
 synthesis of an ornithine lipid in *Pseudomonas aeruginosa* during growth under phosphate-limiting conditions,
 but is not involved in antimicrobial peptide susceptibility, FEMS microbiology letters, 320 (2011) 95-102.
- 633 [28] I. Barák, K. Muchová, The role of lipid domains in bacterial cell processes, Int. J. Mol. Sci., 14 (2013) 4050-634 4065.
- [29] L.Y. Baker, C.R. Hobby, A.W. Siv, W.C. Bible, M.S. Glennon, D.M. Anderson, S.J. Symes, D.K. Giles, *Pseudomonas aeruginosa* responds to exogenous polyunsaturated fatty acids (PUFAs) by modifying
 phospholipid composition, membrane permeability, and phenotypes associated with virulence, BMC Microbiol,
 18 (2018) 117.
- 639 [30] C. Sohlenkamp, O. Geiger, Bacterial membrane lipids: diversity in structures and pathways, FEMS Microbiol
- 640 Rev, 40 (2016) 133-159.
- [31] P.J. Wilderman, A.I. Vasil, W.E. Martin, R.C. Murphy, M.L. Vasil, *Pseudomonas aeruginosa* synthesizes
 phosphatidylcholine by use of the phosphatidylcholine synthase pathway, Journal of bacteriology, 184 (2002)
 4792-4799.
- 100 Page 25 | 42
- 101
- 102

- 103
- 644 [32] Y.M. Zhang, C.O. Rock, Membrane lipid homeostasis in bacteria, Nat. Rev. Microbiol., 6 (2008) 222-233.
- 645 [33] H. Goldfine, Membrane Lipid Biogenesis, in: O. Geiger (Ed.) Biogenesis of Fatty Acids, Lipids and 646 Membranes, Springer International Publishing, Cham, 2016, pp. 1-14.

[34] T. Romantsov, J.M. Wood, Contributions of Membrane Lipids to Bacterial Cell Homeostasis upon Osmotic
Challenge, in: O. Geiger (Ed.) Biogenesis of Fatty Acids, Lipids and Membranes, Springer International
Publishing, Cham, 2016, pp. 1-22.

[35] R.N. Lewis, R.N. McElhaney, Surface charge markedly attenuates the nonlamellar phase-forming
 propensities of lipid bilayer membranes: calorimetric and (31)P-nuclear magnetic resonance studies of mixtures
 of cationic, anionic, and zwitterionic lipids, Biophys. J., 79 (2000) 1455-1464.

653 [36] N.C.f.B.I.P. Database, Carbenicillin, CID=20824 in.

[37] P. Pusic, E. Sonnleitner, B. Krennmayr, D.A. Heitzinger, M.T. Wolfinger, A. Resch, U. Blasi, Harnessing
Metabolic Regulation to Increase Hfq-Dependent Antibiotic Susceptibility in *Pseudomonas aeruginosa*, Frontiers
in microbiology, 9 (2018) 2709.

657 [38] Y. Diaz Iglesias, F. Van Bambeke, Activity of Antibiotics against *Pseudomonas aeruginosa* in an In Vitro

658 Model of Biofilms in the Context of Cystic Fibrosis: Influence of the Culture Medium, Antimicrob. Agents

659 Chemother., 64 (2020) e02204-02219.

107

661	Supplementary Information S1: SCFM and SCFM-PC preparation
662	Stock solutions preparation for the SCFM medium
663	Part I: amino acids
664	Solutions can be kept in the dark at 4 °C for less than two months.

665 Amino acids stock solution to dilute into 100 mL of Mili-Q water

amino acid	m (g)
Alanine	1.60
Arginine – HCl	0.63
Cysteine – HCl	0.32
Glutamate – HCl	2.75
Glycine	0.90
Histidine – HCl	0.96
Lysine – HCl	3.84
Methionine	0.90
Ornithine – HCl	1.18
Proline	1.96
Serine	1.47
Threonine	1.19
Valine	1.29

Note: a few minutes of mixing at 37°C can help the dissolution of the amino acids.

668 Isoleucine and phenylalanine stock solution to dilute into <u>100 mL</u> of Mili-Q water

		amino acid	m (g)
		Isoleucine	1.44
		Phenylalanine	0.83
)			
)	Leucine stock solution to dilu	ite into <u>200 mL</u> of Mi	li-Q water

amino acid	m (g)	
Leucine	2.62	

Page 27 | 42

Using Mili-Q water, prepare the following NaOH solutions for the last 3 amino acids

674 solutions

C (mol/L)	V (L)	m (g)
1	0.10	4.00
0.5	0.10	2.00
0.2	0.10	0.80

675

111

676 Aspartate stock solution to dilute into 50 mL of NaOH 0.5 M

amino acid	m (g)	
Aspartate	0.69	

678 Tyrosine stock solution to dilute into <u>50 mL of NaOH 1 M</u>679

		amino acid	m (g)
		Tyrosine	0.91
680			
681	Tryptophan stock solution to	o dilute into <u>50 mL of</u>	NaOH 0.2 M
682			
		amino acid	m (g)
		Tryptophan	1.33
683			
684			
685			

112

113

686Part II: salts and others687Solutions can be kept in the dark at 4 °C for less than two months.

688 Mixed salts stock solution to dilute into 500 mL of Mili-Q water

689 This solution can be autoclave sterilised for storage purpose.

Salt	m (g)
NH₄Cl	0.61
KCI	5.70
NaCl	14.92
NaH_2PO_4	0.78
Na_2HPO_4	0.72
K_2SO_4	0.24
NaNO ₃	0.15

690

691 Morpholinepropanesulfonic acid (MOPS) to dilute into <u>250 mL of Mili-Q water</u>

692 This solution can be autoclave sterilised for storage purpose.

Buffer	m (g)
MOPS	5.23

693

694 CaCl₂/ MgCl₂ stock solution to dilute into <u>25 mL of Mili-Q water</u>

695 **Filter sterilise through a 0.22-μm-pore-size filter.**

696

Salt	m (g)
$CaCl_2$	2.43
MgCl ₂	0.72

697

FeSO4 stock solution to dilute into <u>an autoclave sterilised bottle using 100 mL of autoclave</u>
 <u>sterilised Mili-Q water</u>

Regularly check for precipitation; prepare fresh stock solution in case of precipitation.

Salt	m (g)
FeSO₄	0.10

1	1	6

117 118 Page 29 | 42

- 702 D-glucose stock solution to dilute to 50 mL using Mili-Q water
- 703 Filter sterilise through a 0.22-μm-pore-size filter.

704

Sugar	m (g)
D-glucose	9.01

705

706 60 % (w/w) Sodium L-Lactate to dilute to 10 % (w/w) using Mili-Q water

707 Filter sterilise through a 0.22-μm-pore-size filter.

708

Page 30 | 42

120

709		SCFM preparation	
710	This medium nee	ds to be prepared in steril	e conditions.
711			
	Stock solution	V for 1 L of SCFM	V for 330 mL of SCFM
	Mixed salts	100 mL	33 mL

Mixe	d salts	100 mL	33 mL												
Μ	OPS	25 mL	8.25 mL												
Mili-0) water	805 mL	265 mL												
Mixed a	mino acids	10 mL	3.3 mL												
Isoleucine +	Phenylalanine	10 mL	3.3 mL												
Leu	icine	16 mL	5.28 mL												
Asp	artate	8 mL	2.64 mL												
Tyr	osine	8 mL	2.64 mL												
Trypt	ophan	0.1 mL	33 μL												
	Autoclave sterilise														
١	Wait for the medium to cool to room temperature														
Adjust p	Adjust pH to 6.5 using HCl 33 % w/w (approx. 600 μL for 330 mL)														
CaCl ₂	/ MgCl ₂	2 mL	0.66 mL												
Fe	SO ₄	1 mL	0.33 mL												
D-gl	ucose	3 mL	0.99 mL												
Sodium	L-lactate	10.5 mL	3.5 mL												
712															
710															
713															
714															

716	Before SCFM-PC preparation
717	
718	/!\1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) should be Avanti polar Lipids quality.
719	Make DOPC aliquots of 10mg or 33mg (depends on the required volume of SCFM-PC
720	required; in SCFM-PC, DOPC is at a final concentration of 100µg/mL), in chloroform, at
721	approximately 250 mg/mL.
722	Stock these aliquots in chloroform, under argon, at −20°C, in the dark.
723	
724	SCFM-PC preparation
725	
726	In order to add the aliquot of DOPC to SCFM (SCFM not older than 3 weeks):
727	/!\ Use an erlenmeyer or a bottle at least 3 times bigger than the volume of required SCFM-
728	PC.
729	Under a biosafety cabinet:
730	1 Rince Paster pipette several times with chloroform,
731	2 Add DOPC slowly 20µL per 20µL, making it run along the inside of the Erlenmeyer flask —in
732	order to evaporate the chloroform,
733	/!\ Lipid traces and lipid droplets will be visible on the inside of the flask, and in the bottom
734	of the flask, respectively.
735	3 Gently manually shake to "rinse" the lipids traces,
736	4 Shake until lipids droplets can't be seen anymore: the medium will appear cloudy.
737	If lipids drops are hard to dissolve, alternate shaking and resting (5 min) under the biosafety
738	cabinet: This allows to evaporate last traces of chloroform which are trapped in lipid vesicles.
739	Note: If the lipid droplets are fully dissolved, the medium can be stored a week, at 4°C, in the
740	dark!
128	Page 32 42
129 130	
100	




Fig. S2.1. Mass spectra, in ion negative mode, of SCFM media collected during preparation, before (A) or after (B) autoclave sterilisation. The ions detected whose m/z are specified correspond to the deprotonated molecules [M-H]⁻ of the amino acids.




Fig. S2.2. Optical Density (A) or Colony Forming Unit (B) plotted against growth time for PAK
grown into SCFM autoclave sterilised (red squares) or filtered sterilised (green triangles).
Experiments were made in biological triplicates. Standard deviations are represented by
error bars.






Fig S2.3. Optical images of PAK grown into: A. MHB, B. SCFM, C. SCFM-PC. Influence on the biofilm production depending on the growth medium was observed. Less biofilm were observed for PAK grown into MHB rather than in SCFM or in SCFM-PC. In SCFM-PC, bacterial colonies were smaller and more dispersed than the ones observed in the other two media.

136

Page 34 | 42








Fig S2.4. Relative areas of phosphatidylcholines extracted from PAK grown into MHB (black), SCFM (red) or SCFM-PC (blue). Error bars: standard deviation (7≤n≤9). P-values are reported —between MHB and SCFM, SCFM and SCFM-PC and MHB and SCFM-PC— as: * for p<0.05, ** for p<0.01, *** for p<0.001, ns for non-significant. Page 35 | 42

765





766

Fig S2.5. Relative areas of phosphatidylethanolamines extracted from PAK grown into MHB (black), SCFM (red) or SCFM-PC (blue). Error bars: standard deviation ($7 \le n \le 9$). P-values are reported —between MHB and SCFM, SCFM and SCFM-PC and MHB and SCFM-PC— as: * for p<0.05, ** for p<0.01, *** for p<0.001, ns for non-significant.




Fig S2.6. Relative areas of phosphatidylglycerols extracted from PAK grown into MHB (black),
SCFM (red) or SCFM-PC (blue). Error bars: standard deviation (7≤n≤9). P-values are reported
—between MHB and SCFM, SCFM and SCFM-PC and MHB and SCFM-PC— as: * for p<0.05,
** for p<0.01, *** for p<0.001, ns for non-significant.




Fig S2.7. Relative areas of cardiolipins extracted from PAK grown into MHB (black), SCFM (red) or SCFM-PC (blue). Error bars: standard deviation ($3 \le n \le 6$).). P-values are reported — between MHB and SCFM, SCFM and SCFM-PC and MHB and SCFM-PC— as: * for p<0.05, ** for p<0.01, *** for p<0.001, ns for non-significant.

152	Page 38 42
153	
154	

Supplementary Information S3: MS/MS

Full Excel file downloadable at https://doi.org/10.1016/j.bbamem.2020.183482

FA: Fatty Acid		iso1: most in	tense isomer		iso2: second most intense isomer nd: not detected																
PC 32:1 PC 16:0/16:1										PC 14:0/18:1											
Growth medium - replicates	Phospholipid fragment		FA(iso1) sn2				FA(iso1) sr	11	sn-1/sn-2 ratio (isomer 1)		FA(iso2) sn2		FA(iso2) sn1			isomer 2/ isomer 1 ratio		sn-1/sn-2 ratio (isomer 2)			
Г	m/z	intensity	identification	m/z	intensity	identification	m/z	intensity	identification			m⁄z	intensity	identification	m/z	intensity	identification				
PAK - MHB1 PAK - MHB2 PAK - MHB3	716.5381	50 203 257	PC 32:1-CH3	253.2192	341 4384 3414	16:1	nd nd nd	nd nd nd	nd nd nd			281.2545	157 1485 1740	18:1	227.2069	131 440 487	14:0	18:1/16:1 average std dev RSD %	0.46 0.33 0.51 0.43 0.09 20.82	14:0/18:1 average std dev RSD %	0.83 0.30 0.28 0.47 0.31 66.68
PAK - SCFM-PC1 PAK - SCFM-PC2 PAK - SCFM-PC3	716.5381	25 75 303	PC 32:1-CH3	253.2192	573 953 1392	16:1	255.2407	159 616 1175	16:0	16:0/16:1 average std dev RSD %	0.28 0.65 0.84 0.59 0.29 48.80	281.2545	1529 3719 6302	18:1	227.2069	47 373 1286	14:0	18:1/16:1 average std dev RSD %	2.67 3.90 4.53 3.70 0.95 25.57	14:0/18:1 average std dev RSD %	0.03 0.10 0.20 0.11 0.09 78.09

	PC 34:1 PC 18:1/16:0											PC 18:0/16:1							
Growth medium - replicates	Pho	ospholipid fra	gment	FA(iso1) sn2		FA(iso1) sn1		sn-1/sn-2 ratio (isomer 1)		FA(iso2) sn2				FA(iso2) sn1		isomer 2/ isomer 1 ratio			
	m/z	intensity	identification	m⁄z	intensity	identification	m/z	intensity	identification			m⁄z	intensity	identification	m/z	intensity	identification		-
PAK - MHB1		700			2492			2104			0.84		26		nd	nd	nd		0.01
PAK - MHB2	744.5784	2556	PC 34:1-CH3	255.2475	12843	16:0	281.2545	7448	18:1	18:1/16:0	0.58	253.2261	216	16:1	nd	nd	nd	16:1/16:0	0.02
PAK - MHB3		2168			13518			7568			0.56		222		nd	nd	nd		0.02
										average	0.66							average	0.01
										std dev	0.16							std dev	0.00
										RSD %	24.00							RSD %	24.57
PAK - SCFM-PC1		1041			4457	16:0		4662			1.05	nd	nd	nd	nd	nd	nd	nd	nd
PAK - SCFM-PC2	744.5784	3835	PC 34:1-CH3	255.2475	20425	16:0	281.2545	17718	18:1	18:1/16:0	0.87	253.2261	73	16:1	nd	nd	nd	16:1/16:0	0.00
PAK - SCFM-PC3		10562			46507	16:0		40921			0.88	200.2201	43	10.1	nd	nd	nd	10.1710.0	0.00
							Note: in SCF	Note: in SCFM-PC, close abundance of		average	0.93							average	0.00
								1/16:0 & PC		std dev	0.10							std dev	0.00
							(sn-1/	/sn-2 ratio clo	se to 1)	RSD %	10.71							RSD %	83.29

Page 39 | 42

1	5	9

	PC 34	:2		PC 18:1/16:0									PC 17:1/17:1					
Growth medium -	Phospholipid fragment			FA(iso1) sn2			FA(iso1) sn1			sn-1/sn-2 ratio		FA	(iso2) sn2 (isomer 2/ isomer 1				
replicates	m/z	intensity	identification	m/z	intensity	identification	m/z	intensity	identification	(Isome	(isomer 1)		intensity	identification	rat	10		
PAK - MHB1 PAK - MHB2 PAK - MHB3	742.5516	157 545 465	PC 34:2-CH3	253.2261	682 4380 4299	16:1	281.2545	853 1551 1435	18:1	18:1/16:1 average std dev RSD %	1.25 0.35 0.33 0.65 0.52 81.03	nd 267.2387	nd 295 262	nd 17:1	nd 17:1/16:1 average std dev RSD %	nd 0.07 0.06 0.06 0.00 7.06		
PAK - SCFM-PC1 PAK - SCFM-PC2 PAK - SCFM-PC3	742.5516	133 779 1660	PC 34:2-CH3	253.2261	1057 3909 11447	16:1	281.2545	649 2411 7830	18:1	18:1/16:1 average std dev RSD %	0.61 0.62 0.68 0.64 0.04 6.21	nd 267.2387	nd 45 31	nd 17:1	nd 17:1/16:1 average std dev RSD %	nd 0.01 0.00 0.01 0.01 87.56		

	PC 36	PC 18:1/18:1							
Growth medium -	Pho	spholipid frag	ment	FA sn2 & sn1					
replicates	m/z	intensity	identification	m/z	intensity	identification			
PAK - MHB1		8062			57703				
PAK - MHB2	770.6135	3896	PC 36:2-CH3	281.2545	27941	18:1			
PAK - MHB3		1291			7516				
PAK - SCFM-PC1		859538			88528				
PAK - SCFM-PC2	770.6135	47975	PC 36:2-CH3	281.2545	6021	18:1			
PAK - SCFM-PC3		12052			15605				

Т	ь	3

799

EA: Eatty Acid		
	FA: Fatty Acid	

iso1: most intense isomer

iso2: second most intense isomer

iso3: third most intense isomer

nd: not detected

PE 36:2	P	E 18:1/18	3:1					PE 19	:1/17:1				PE 20:1/16:1									
Growth medium -	FA(iso2) sn2 (& sn1		FA(iso2) s	n2	FA(iso2) sn1			isomer 2/ isomer 1 sn-1/sn-2 ratio (iso			atio (iso2)	F	A(iso3) sn2			FA(iso3) s	sn1	Isomer 3/ isomer 1 ratio		
replicates	m/z	intensity	identification	m/z	intensity	identification	m/z	intensity	dentification	n.	ratio				intensity	dentificatio	m/z	intensity	identification			
PAK - MHB1		579		nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	
PAK - MHB2	281.2545	8579	18:1	267.2331	733	17:1	295.2615	214	19:1	17:1/18:1	0.09	19:1/17:1	0.29	253.2139	75	16:1	nd	nd	nd	16:1/18:1	0.01	
PAK - MHB3		8188		207.2351	490	17.1	285.2015	299	10.1	17.1/10.1	0.06	18.1/17.1	0.61	200.2108	86	10.1	nd	nd	nd	10.1/10.1	0.01	
										average	0.07	average	0.45							average	0.01	
										std dev	0.02	std dev	0.23							std dev	0.00	
										RSD %	24.92	RSD %	49.89							RSD %	12.94	
PAK - SCFM 1		5143			251		295.2615	59	19:1		0.05	19:1/17:1	0.24		26		nd	nd	nd		0.01	
PAK - SCFM 2	281.2545	4380	18:1	267.2331	324	17:1	200.2010	56		17:1/18:1	0.07		0.17	253.2139	94	16:1	nd	nd	nd	16:1/18:1	0.02	
PAK - SCFM 3		1887			59		nd	nd	nd		0.03	nd	nd		43		nd	nd	nd		0.02	
										average	0.05	average	0.20							average	0.02	
										std dev	0.02	std dev	0.04							std dev	0.01	
										RSD %	41.81	RSD %	21.57							RSD %	60.10	
PAK - SCFM-PC1		96226		267.2331	953	17:1	295.2615	370	19:1	17:1/18:1	0.01	19:1/17:1	0.39	253.2139	66	16:1	nd	nd	nd	16:1/18:1	0.00	
PAK - SCFM-PC2	281.2545	25714	18:1	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	nd	
PAK - SCFM-PC3		53411		267.2331	120	17:1	295.2615	51	19:1	17:1/18:1	0.00	19:1/17:1	0.43	253.2139	34	16:1	nd	nd	nd	16:1/18:1	0.00	
										average	0.01	average	0.41							average	0.00	
										std dev	0.01	std dev	0.03							std dev	0.00	
										RSD %	89.12	RSD %	6.39							RSD %	5.27	
								RSD %	19.43							D D D	D%	15.02 R	SD % 1	.94		
								30 %	10.40							1 10	0 %	13.02	1.00 % 1.	.34		

PE 34:1				PE 18:	1/16:0				PE 18:0/16:1							
Growth medium -		FA(iso1) sn2			FA(iso1) sn1			sn-1/sn-2 ratio		FA(iso2) si	12		FA(iso2) s	isomer 2/ isomer 1 ratio		
replicates	m/z	intensity	identification	m/z	intensity	identification				intensity	identification	m/z	intensity	identification	rau	•
PAK - MHB1		4735			2796			0.59		202		nd	nd	nd		0.04
PAK - MHB2	255.2475	70116	16:0	281.2545	41641	18:1	18:1/16:0	0.59	253.2261	2199	16:1	nd	nd	nd	16:1/16:0	0.03
PAK - MHB3		69139			42671			0.62		2314		nd	nd	nd		0.03
							average	0.60							average	0.04
							std dev	0.01							std dev	0.01
							RSD %	2.42							RSD %	16.77
PAK - SCFM 1		77871			38154			0.49		2273		nd	nd	nd		0.03
PAK - SCFM 2	255.2475	80899	16:0	281.2545	30060	18:1	18:1/16:0	0.37	253.2261	2128	16:1	nd	nd	nd	16:1/16:0	0.03
PAK - SCFM 3		38588			17722			0.46		907		nd	nd	nd		0.02
							average	0.44							average	0.03
							std dev	0.06							std dev	0.00
							RSD %	13.95							RSD %	10.79
PAK - SCFM-PC1		732023			535977			0.73		7356		nd	nd	nd		0.01
PAK - SCFM-PC2	255.2475	421282	16:0	281.2545		18:1	18:1/16:0	0.95	253.2261	1917	16:1	nd	nd	nd	16:1/16:0	0.00
PAK - SCFM-PC3		368937			396739			1.08		1205		nd	nd	nd		0.00
				Note: In SC	Note: In SCFM-PC, close abundance			0.92							average	0.01
						16:0/18:1 (sn-	std dev	0.17							std dev	0.00
				1/sn	-2 ratio clos	se to 1)	RSD %	18.90							RSD %	60.50

164

165

Page 41 | 43

FA: Fatty Acid		iso1: r	most intense i	somer		iso2: secon	id most inte	nse isome	er	iso3: thir	rd most intens	e isomer		nd: not detec	ted			
PG 32:1				PG 16	:0/16:1								PG 14:	0/18:1				
Growth medium -		FA(iso1) s	in2		FA(iso1)	sn1	sn-1/sn-			FA(iso2) s	in2		FA(iso2) si	n1	isomer 2/		sn-1/sn-	
replicates	m/z		identification	m/z		identification	(iso	1)	m/z		identification	m/z		identification	rat	0	(iso)	· ·
PAK - MHB1		595			215			0.36		124			56			0.21		0.45
PAK - MHB2	253.2192		16:1	255.229	2606	16:0	16:0/16:1	0.40	227.2069	1820	14:0	281.2412		18:1	14:0/16:1	0.28	18:1/14:0	
PAK - MHB3		5617			2592			0.46		1500			832			0.27		0.55
							average	0.41							average	0.25	average	0.51
							std dev	0.05							std dev	0.04	std dev	0.05
							RSD %	12.30							RSD %	15.38	RSD %	10.29
PAK - SCFM 1		7023			3336			0.48		2313			887			0.33		0.38
PAK - SCFM 2	253.2192		16:1	255.229	3123	16:0	16:0/16:1	0.36	227.2069	1924	14:0	281.2412		18:1	14:0/16:1	0.22	18:1/14:0	
PAK - SCFM 3		2263			1125			0.50		764			276			0.34		0.36
							average	0.44							average	0.30	average	0.40
							std dev	0.07							std dev	0.06	std dev	0.05
							RSD %	16.73							RSD %	21.96	RSD %	12.02
PAK - SCFM-PC1		12412	10.1	055.000	5964	40.0	10.040.1	0.48	007.0000	4368			2852	10.1		0.35	10.111.0	0.65
PAK - SCFM-PC2 PAK - SCFM-PC3		708 1706	16:1	255.229	503 1172	16:0	16:0/16:1	0.69	227.2069	601 1198	14:0	281.2412	603 1068	18:1	14:0/16:1	0.85 0.70	18:1/14:0	1.00 0.89
PAK - SUPM-PUS		1/00			11/2					1198			1008					
							average	0.63							average	0.63	average	0.85
							std dev	0.13							std dev	0.26	std dev	0.18
							RSD %	20.21							RSD %	40.25	RSD %	21.07

PG 34:1				PG 18:	:1/16:0				PG 18:0/16:1							
Growth medium -	FA(iso1) sn2 FA				FA(iso1)	A(iso1) sn1 sn-1/sn-2 ratio				FA(iso2) s	in2		FA(iso2) sr	isomer 2/ isomer 1		
replicates	m/z	intensité	identification	m/z	intensité	identification	(ISO	(iso1)		intensité	identification	m/z	intensité	identification	rat	10
PAK - MHB1		1175			660			0.56		115		nd	nd	nd		0.10
PAK - MHB2	255.2475	14066	16:0	281.255	9955	18:1	18:1/16:0	0.71	253.2261	1202	16:1	nd	nd	nd	16:1/16:0	0.09
PAK - MHB3		14509			10167			0.70		828		nd	nd	nd		0.06
							average	0.66							average	0.08
							std dev	0.08							std dev	0.02
							RSD %	12.54							RSD %	26.10
PAK - SCFM 1		23192			13486			0.58		1283		nd	nd	nd		0.06
PAK - SCFM 2	255.2475	23202	16:0	281.255	11623	18:1	18:1/16:0	0.50	253.2261	1012	16:1	nd	nd	nd	16:1/16:0	0.04
PAK - SCFM 3		8496			4613			0.54		601		nd	nd	nd		0.07
							average	0.54							average	0.06
							std dev	0.04							std dev	0.01
							RSD %	7.44							RSD %	24.05
PAK - SCFM-PC1		31396			32177			1.02		413		nd	nd	nd		0.01
PAK - SCFM-PC2	255.2475	129379	16:0	281.255	138995	18:1	18:1/16:0	1.07	253.2261	1312	16:1	nd	nd	nd	16:1/16:0	0.01
PAK - SCFM-PC3		171763			184963			1.08		1427		nd	nd	nd		0.01
					In SCFM-		average	1.06							average	0.01
						1/16:0 & PG	std dev	0.03							std dev	0.00
				16:0/18:1 (sn-1/sn-2 r	atio close to 1)	RSD %	2.77							RSD %	23.23

Page 42 | 42